Jean-Luc Harousseau, MD, from the University of Nantes, Nantes, France, discusses the differences in the evaluation of value of new agents across Europe at the 2017 annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Marseille, France. He explains that some health technology assessments (HTA) are based on clinical evaluation alone, while other assessments are based on health economic evaluation. Prof. Harousseau points out the differences in assessments between different countries, and concludes that this makes harmonization of health technology assessment evaluations across Europe a challenge.

Leave a comment